Intensity Therapeutics Inc. announced on May 19, 2025, that it received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC, indicating the company is not in compliance with the minimum stockholders' equity requirement necessary for continued listing on The Nasdaq Capital Market. The notice follows the company's latest quarterly report, which revealed it did not meet the Nasdaq Listing Rule 5550(b)(1) criteria. Intensity Therapeutics has until July 3, 2025, to submit a plan to regain compliance. If accepted, the company could receive a 180-day extension to meet the requirements. The notice does not immediately affect the company's listing, but failure to comply may lead to delisting, subject to appeal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.